LAG3 and neoplasm: LAG-3 interacts specifically with tumor cells and antigen-presenting cells (APCs) via the major histocompatibility complex class II (MHC-II) [63,64], which triggers co-inhibitory signaling pathways and ultimately results in T cell alterations [65,66].